Citadel Advisors
ZIVO

Citadel Advisors’s Zivo Bioscience, Inc. Common Stock ZIVO Stock Holding History

Citadel Advisors’s Portfolio ZIVO Stock Details ZIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,247
Closed -$73K – 14918
2021
Q4 		$73K Buy
+4,247
New +$88.9K ﹤0.01% 13009

Other funds holding ZIVO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BC
Bartlett & Co Cincinnati, Ohio $6.16B AUM 20.29% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.82B AUM 15.4% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Citadel Advisors's ZIVO Position: Q1 2022 in Review

Citadel Advisors sold out of Zivo Bioscience, Inc. Common Stock (ZIVO) in Q1 2022, closing a stake of 4,247 shares — an estimated $73K sold.

Citadel Advisors first reported a position in ZIVO in Q4 2021 and held it in 1 quarter. The position peaked at $73K in Q4 2021. 12 funds tracked by Wall St. Rank hold ZIVO as of Q1 2022.

  • Citadel Advisors reported no remaining Zivo Bioscience, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Citadel Advisors sold 4,247 Zivo Bioscience, Inc. Common Stock shares in Q1 2022, an estimated $73K.
  • Citadel Advisors first reported a position in Zivo Bioscience, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Citadel Advisors's Zivo Bioscience, Inc. Common Stock position peaked at $73K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Zivo Bioscience, Inc. Common Stock as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.